A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive
Authors:
- B.M. BradyBBB.M. Brady
- J.K. AmoryJAJ.K. Amory
- A. PerheentupaAPA. Perheentupa
- M. ZitzmannMZM. Zitzmann
- C.J. HayCHC.J. Hay
- D. ApterDAD. Apter
Open Access
- 19 September 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 21 (1) , 285-294
Abstract
BACKGROUND: The combination of etonogestrel implants with injectable testosterone decanoate was investigated as a potential male contraceptive. METHODS: One hundred and thirty subjects were randomly assigned to three treatment groups, all receiving two etonogestrel rods (204 mg etonogestrel) and 400 mg testosterone decanoate either every 4 weeks (group I, n = 42), or every 6 weeks (group II, n = 51) or 600 mg testosterone decanoate every 6 weeks (group III, n = 37) for a treatment period of 48 weeks. RESULTS: One hundred and ten men completed 48 weeks of treatment. Sperm concentrations of 6/ml were achieved in 90% (group I), 82% (group II) and 89% (group III) of subjects by week 24. Suppression was slower in group II, which also demonstrated more frequent escape from gonadotrophin suppression than groups I and III. Peak testosterone concentrations remained in the normal range throughout in all groups. Mean trough testosterone concentrations were initially subphysiological but increased into the normal range during treatment. Mean haemoglobin levels increased in group I, and a non-significant increase in weight and decline in high-density lipoprotein cholesterol was observed in all groups. Fourteen subjects discontinued treatment due to adverse events. CONCLUSIONS: Subcutaneous etonogestrel implants in combination with injectable testosterone decanoate resulted in profound suppression of spermatogenesis that could be maintained for up to 1 year. Efficacy of suppression was less in group II, probably due to inadequate testosterone dosage. This combination has potential as a long-acting male hormonal contraceptive.Keywords
This publication has 36 references indexed in Scilit:
- Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraceptionHuman Reproduction, 2004
- Male ContraceptionEndocrine Reviews, 2002
- Investigation of a novel preparation of testosterone decanoate in men: pharmacokinetics and spermatogenic suppression with etonogestrel implantsContraception, 2002
- Suppression of Spermatogenesis by Etonogestrel Implants with Depot Testosterone: Potential for Long-Acting Male ContraceptionThe Journal of Clinical Endocrinology & Metabolism, 2002
- Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppressionFertility and Sterility, 2000
- Progesterone Action in a Murine Leydig Tumor Cell Line (mLTC-1), Possibly through a Nonclassical Receptor Type1Endocrinology, 2000
- Progesterone can participate in down-regulation of the luteinizing hormone receptor gene expression and function in cultured murine Leydig cellsMolecular and Cellular Endocrinology, 1998
- The derogatis interview for sexual functioning (DISF/DISF-SR): An introductory reportJournal of Sex & Marital Therapy, 1997
- Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulinAmerican Journal of Obstetrics and Gynecology, 1990
- Study of medroxyprogesterone acetate and testosterone enanthate as a male contraceptiveContraception, 1977